Logo image
Se connecter
Retour
Safety and Immunogenicity of Respiratory Syncytial Virus Prefusion F Protein Vaccine when Co-administered with Adjuvanted Seasonal Quadrivalent Influenza Vaccine in Older Adults: A Phase 3 Randomized Trial
Article de revue   Avec comité de lecture

Safety and Immunogenicity of Respiratory Syncytial Virus Prefusion F Protein Vaccine when Co-administered with Adjuvanted Seasonal Quadrivalent Influenza Vaccine in Older Adults: A Phase 3 Randomized Trial

Rebecca Clark, Sam Davies, Jorge Labrador, Paul Loubet, Silvina Natalini Martínez, Helena Moza Moríñigo, Jean-François Nicolas, Mercè Pérez Vera, Mika Rämet, Maria Henar Rebollo-Rodrigo, …
Clinical infectious diseases, Vol.79(4), pp.1088-1098
15/10/2024
DOI: https://doi.org/10.1093/cid/ciae365
PMID: 39099085

Résumé

Major
Respiratory syncytial virus prefusion F protein-based vaccine (RSVPreF3 OA) and adjuvanted seasonal quadrivalent influenza vaccine had acceptable safety profiles when co-administered in adults ≥65 years of age, without clinically relevant interference with the immune responses to either vaccine. Graphical Abstract

Indicateurs

1 Consultations de la notice

Détails

Logo image